Breaking News, Collaborations & Alliances

Matica Bio, CytoImmune Partner to Advance Clinical Cell Therapy Program

Matica Bio will produce viral vectors at its GMP facility, while CytoImmune will manufacture its cell therapy at its Puerto Rico facility for IND submission.

Author Image

By: Charlie Sternberg

Associate Editor

Matica Biotechnology Inc., a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing, has entered a strategic development partnership with CytoImmune, a biotechnology company based in Puerto Rico that focuses on innovative cell therapies for cancer treatment using proprietary technology.   Under this partnership, Matica Bio will produce viral vectors at its purpose-built GMP facility, while CytoImmune will manufacture its cell therapy at its Puerto...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters